Back to results
US 11,028,441 B2Granted
IL-10 as a predictive biomarker of responsiveness to house dust mite allergen immunotherapy
AssigneeStallergenes
InventorsLaurent Mascarell, Véronique Bodo, Philippe Moingeon, Vincent Lombardi, Claire Gueguen
Life of this patent
Estimating the term…
Abstract
The present invention concerns the use of IL-10 as a biological marker for predicting the responsiveness of a house dust mite allergic patient to house dust mite allergen immunotherapy.
Claims4
A method for immunotherapy of house dust mite allergy in a patient comprising:
- (i) selecting a patient for immunotherapy by implementing a method comprising:
- a) measuring abundance of IL-10 mRNA in a biological sample from said patient,
- b) comparing said abundance of IL-10 mRNA with a control,
- c) identifying said patient as likely to be a responder to immunotherapy when
- (c1) the abundance of IL-10 mRNA in the patient sample is equal to or greater than the level of expression in a control derived from a responder subject, or group of responder subjects, known to respond to said immunotherapy;
- or
- (c2) the abundance of IL-10 mRNA in the patient sample is greater than the level of expression in a control derived from a non-responder subject, or group of non-responder subjects;
- or
- (c3) the abundance of IL-10 mRNA in the patient sample is greater than the level of expression in a control derived from a randomly selected group of subjects;
- and
- wherein said biological sample is taken before the commencement of immunotherapy, and wherein said immunotherapy comprises administration of a house dust mite allergen to said patient in order to treat house dust mite allergy, and
- (ii) administering said house dust mite allergen to said patient identified as likely to be a responder to said immunotherapy.
9 more elements
Dependencies are inferred from the claim text.